

15<sup>th</sup> May, 2018

The Dy. General Manager (Listing Dept.)  
BSE Limited  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

**Sub Intimation of the date of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) and Closure of Trading Window as per Company’s Code of Conduct to Regulate, Monitor and Report Trading by Insiders**

---

We would like to inform you that:

1. A meeting of the Board of Directors will be held on Wednesday, 30-May-18, inter alia to consider and approve the Audited Financial Results for the year ended 31-Mar-18.
2. In the above meeting, the Board would also consider the recommendation of Final Dividend for the year ended 31-Mar-18.
3. As per the provisions of the Code of Conduct to Regulate, Monitor and Report Trading by Insiders of the Company, the trading window shall be closed from 16-May-18 to 01-Jun-18.

Kindly take note of the above.

Thanking you,

Yours Sincerely,  
For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY